Nov 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 3RD QUARTER FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.00.Q3 REVENUE $1.373 BILLION VERSUS I/B/E/S VIEW $1.42 BILLION.SEES FY 2018 LOSS PER SHARE $0.10 TO $+0.03.SEES FY 2018 REVENUE $5.5 BILLION TO $5.7 BILLION.Q3 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S.
Full Article
April 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC FILES FOR POTENTIAL STOCK SHELF, SIZE NOT DISCLOSED - SEC FILING.
Full Article
Feb 26 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.18.Q4 EARNINGS PER SHARE $0.09.SEES FY 2018 EARNINGS PER SHARE $0.06 TO $0.17.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.SEES 2018 ADJUSTED EPS BETWEEN $0.87 AND $0.97.REVENUE FOR Q4 OF 2017 WAS $1,155 MILLION, COMPARED TO $1,145 MILLION IN Q4 OF 2016.FY2018 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $5.42 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.16, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.
Full Article
Jan 5 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY.DIPLOMAT PHARMACY INC - PHIL HAGERMAN TO CONTINUE SERVICE ON BOARD AND BECOME CHAIRMAN EMERITUS.DIPLOMAT PHARMACY INC - BOARD HAS APPOINTED BEN WOLIN, INDEPENDENT LEAD DIRECTOR, AS CHAIRMAN OF DIPLOMAT BOARD, EFFECTIVE IMMEDIATELY.DIPLOMAT INITIATES CEO TRANSITION; REAFFIRMS 2017 GUIDANCE AND PROVIDES PRELIMINARY 2018 OUTLOOK.DIPLOMAT PHARMACY - PARK'S APPOINTMENT FOLLOWS RETIREMENT OF PHIL HAGERMAN.DIPLOMAT PHARMACY INC - IN 2018, DIPLOMAT PRELIMINARILY EXPECTS REVENUE IN RANGE OF $5.3 TO $5.6 BILLION.
Full Article
Jan 5 (Reuters) - Diplomat Pharmacy Inc ::- EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE.FY2018 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S.DIPLOMAT REAFFIRMS 2017 GUIDANCE, PROVIDES PRELIMINARY 2018 OUTLOOK.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.- IN 2018, EXPECTS ADJUSTED EBITDA IN RANGE OF $164 TO $170 MILLION.
Full Article
Dec 20 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES.DIPLOMAT PHARMACY INC - ENTERED INTO NEW $800 MILLION SENIOR SECURED CREDIT FACILITIES.DIPLOMAT PHARMACY - $800 MILLION FINANCING COMPRISED OF $250 MILLION REVOLVING CREDIT FACILITY, $150 MILLION TERM LOAN A FACILITY, $400 MILLION TERM LOAN B FACILITY.DIPLOMAT PHARMACY - PROCEEDS OF DEBT FINANCING WILL BE USED TO FINANCE LDI DEAL, REFINANCE DIPLOMAT'S CURRENT INDEBTEDNESS, AMONG OTHERS.
Full Article
Nov 15 (Reuters) - Diplomat Pharmacy Inc :Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat to acquire LDI Integrated Pharmacy Services.Diplomat Pharmacy Inc - will pay LDI $515 million cash and approximately $80 million in diplomat common stock.Diplomat Pharmacy Inc - LDI is expected to generate approximately $388 million in revenue and $41 million in adjusted EBITDA in 2017.Diplomat Pharmacy Inc - cash portion of acquisition is expected to be funded by diplomat's new $795 million senior secured credit facility.
Full Article
Nov 6 (Reuters) - Diplomat Pharmacy Inc :Diplomat announces 3rd quarter financial results.Q3 adjusted earnings per share $0.25.Q3 earnings per share $0.01.Q3 revenue $1.125 billion versus I/B/E/S view $1.16 billion.Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $0.82 to $0.87.Sees FY 2017 earnings per share $0.15 to $0.20.Sees FY 2017 revenue $4.4 billion to $4.6 billion.FY2017 earnings per share view $0.75, revenue view $4.52 billion -- Thomson Reuters I/B/E/S.Diplomat Pharmacy Inc - resolved arbitration with CVS and have transitioned from a PSAO contract to a direct contract with CVS.
Full Article
Nov 6 (Reuters) - Diplomat Pharmacy Inc :Diplomat Pharmacy - entered agreement to acquire Pharmaceutical Technologies Inc, doing business as National Pharmaceutical Services.Diplomat Pharmacy - under the terms of the agreement, Diplomat will pay NPS $31 million cash and $16 million in Diplomat common stock.
Full Article
Aug 15 (Reuters) - Diplomat Pharmacy Inc :Diplomat Pharmacy Inc - now dispensing opioid-overdose antidote naloxone to Michigan residents.
Full Article
Earnings vs. 
Estimates